Figure 1.
Survey of ADAMTS13 inhibitor and anti-ADAMTS13 antibodies on diagnosis in patients with a severe (<5%) or a mild (13–18%) ADAMTS13 deficiency.
Figure 2.
Dark grey squares: deficient ADAMTS13 activity with inhibitory or non-inhibitory anti-ADAMTS13 antibodies; light grey squares: deficient ADAMTS13 activity with suspected inhibitory or non-inhibitory anti-ADAMTS13 antibodies; white squares: detectable (≥20%) ADAMTS13 activity. Grey area delimits ADAMTS13 values of normal subjects. Abbreviation: TMA, thrombotic microangiopathy.
Table 1.
Clinical Characteristics of 214 Patients with Thrombotic Microangiopathy According to ADAMTS13 Activity.
Table 2.
Results of Laboratory Testing in 214 Patients with Thrombotic Microangiopathy According to ADAMTS13 Activity.
Table 3.
Treatment and Outcome in 214 Patients with Thrombotic Microangiopathy According to ADAMTS13 Activity.
Table 4.
Association Between Patient Characteristics and ADAMTS13 Deficiency Using Multivariate Analysis.
Table 5.
Internal Validation to Predict Severe ADAMTS13 Deficiency at Clinical Presentation.